查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1538529

勝胜肽和寡核苷酸 CDMO 市場報告：2030 年趨勢、預測和競爭分析

Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

勝胜肽/寡核苷酸CDMO趨勢與預測

預計到2030年，全球胜肽寡核苷酸CDMO市場將達到約50億美元，2024年至2030年的複合年成長率為11.3%。該市場的主要驅動力是客製化醫療的日益普及、對罕見疾病的興趣日益濃厚以及對胜肽抗病毒藥物的日益關注。全球胜肽寡核苷酸 CDMO 市場的未來充滿希望，製藥和生物製藥公司市場充滿機會。

分段勝胜肽/寡核苷酸CDMO

該研究包括按產品、服務類型、最終用途和地區對全球胜肽和寡核苷酸 CDMO 的預測。

胜肽核苷酸CDMO市場洞察

Lucintel 預測，在預測期內，勝胜肽將繼續成為更大的細分市場。

在預測期內，生物製藥公司可能仍將佔據市場的較大佔有率。

在預測期內，北美仍將是最大的地區。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球胜肽和寡核苷酸 CDMO 市場預計將達到 50 億美元。

Q2.市場成長預測是多少：

A2. 2024年至2030年，全球勝胜肽/寡核苷酸CDMO市場預計將以11.3%的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 該市場的主要驅動力是客製化醫療的日益普及、對罕見疾病的興趣增加以及對胜肽抗病毒藥物的日益關注。

Q4.市場的主要細分市場是：

A4.胜肽寡核苷酸CDMO市場前景廣闊，製藥和生物製藥公司市場充滿機會。

Q5.市場的主要企業是：

A5.勝胜肽/寡核苷酸CDMO的主要企業如下：

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計勝胜肽在預測期內將繼續成為更大的細分市場。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 在預測期內，北美仍將是最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球胜肽/寡核苷酸CDMO市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球勝胜肽/寡核苷酸CDMO市場趨勢（2018-2023）和預測（2024-2030）
  • 全球勝胜肽/寡核苷酸 CDMO 市場（按產品）
    • 胜肽
    • 寡核苷酸
  • 按服務類型分類的全球勝胜肽/寡核苷酸 CDMO 市場
    • 合約開發
    • 契約製造
  • 按最終用途分類的全球胜肽和寡核苷酸 CDMO 市場
    • 製藥公司
    • 生物製藥公司
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球勝胜肽寡核苷酸 CDMO 市場（按地區）
  • 北美勝胜肽/寡核苷酸CDMO市場
  • 歐洲勝胜肽/寡核苷酸CDMO市場
  • 亞太地區胜肽和寡核苷酸CDMO市場
  • 其他區域性勝胜肽/寡核苷酸 CDMO 市場

第5章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球勝胜肽寡核苷酸 CDMO 市場成長機會（按產品）
    • 按服務類型分類的全球胜肽寡核苷酸 CDMO 市場成長機會
    • 全球胜肽寡核苷酸 CDMO 市場成長機會（以最終用途）
    • 全球胜肽寡核苷酸 CDMO 市場成長機會（按地區）
  • 全球胜肽/寡核苷酸CDMO市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球胜肽和寡核苷酸 CDMO 市場的產能
    • 全球胜肽和寡核苷酸 CDMO 市場的併購和合資企業
    • 認證和許可

第7章主要企業概況

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis
簡介目錄

Peptide and Oligonucleotide CDMO Trends and Forecast

The future of the global peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets. The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030 with a CAGR of 11.3% from 2024 to 2030. The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Peptide and Oligonucleotide CDMO by Segment

The study includes a forecast for the global peptide and oligonucleotide CDMO by product, service type, end use, and region.

Peptide and Oligonucleotide CDMO Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Peptides
  • Oligonucleotides

Peptide and Oligonucleotide CDMO Market by Service Type [Shipment Analysis by Value from 2018 to 2030]:

  • Contract Development
  • Contract Manufacturing

Peptide and Oligonucleotide CDMO Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others

Peptide and Oligonucleotide CDMO Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Peptide and Oligonucleotide CDMO Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peptide and oligonucleotide CDMO companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peptide and oligonucleotide CDMO companies profiled in this report include-

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis

Peptide and Oligonucleotide CDMO Market Insights

Lucintel forecasts that peptide will remain larger segment over the forecast period.

Within this market, biopharmaceutical company will remain larger segment over the forecast period.

North America will remain the largest region over the forecast period.

Features of the Global Peptide and Oligonucleotide CDMO Market

Market Size Estimates: Peptide and oligonucleotide CDMO market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Peptide and oligonucleotide CDMO market size by product, service type, end use, and region in terms of value ($B).

Regional Analysis: Peptide and oligonucleotide CDMO market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, service types, end uses, and regions for the peptide and oligonucleotide CDMO market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peptide and oligonucleotide CDMO market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the peptide and oligonucleotide CDMO market size?

Answer: The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030.

Q2. What is the growth forecast for peptide and oligonucleotide CDMO market?

Answer: The global peptide and oligonucleotide CDMO market is expected to grow with a CAGR of 11.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the peptide and oligonucleotide CDMO market?

Answer: The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.

Q4. What are the major segments for peptide and oligonucleotide CDMO market?

Answer: The future of the peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets.

Q5. Who are the key peptide and oligonucleotide CDMO market companies?

Answer: Some of the key peptide and oligonucleotide CDMO companies are as follows:

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis

Q6. Which peptide and oligonucleotide CDMO market segment will be the largest in future?

Answer: Lucintel forecasts that peptide will remain larger segment over the forecast period.

Q7. In peptide and oligonucleotide CDMO market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the peptide and oligonucleotide CDMO market by product (peptides and oligonucleotides), service type (contract development and contract manufacturing), end use (pharmaceutical companies, biopharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peptide and Oligonucleotide CDMO Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Peptide and Oligonucleotide CDMO Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Peptide and Oligonucleotide CDMO Market by Product
    • 3.3.1: Peptides
    • 3.3.2: Oligonucleotides
  • 3.4: Global Peptide and Oligonucleotide CDMO Market by Service Type
    • 3.4.1: Contract Development
    • 3.4.2: Contract Manufacturing
  • 3.5: Global Peptide and Oligonucleotide CDMO Market by End Use
    • 3.5.1: Pharmaceutical Companies
    • 3.5.2: Biopharmaceutical Companies
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Peptide and Oligonucleotide CDMO Market by Region
  • 4.2: North American Peptide and Oligonucleotide CDMO Market
    • 4.2.1: North American Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.2.2: North American Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
  • 4.3: European Peptide and Oligonucleotide CDMO Market
    • 4.3.1: European Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.3.2: European Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
  • 4.4: APAC Peptide and Oligonucleotide CDMO Market
    • 4.4.1: APAC Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.4.2: APAC Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
  • 4.5: ROW Peptide and Oligonucleotide CDMO Market
    • 4.5.1: ROW Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.5.2: ROW Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Product
    • 6.1.2: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Service Type
    • 6.1.3: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by End Use
    • 6.1.4: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Region
  • 6.2: Emerging Trends in the Global Peptide and Oligonucleotide CDMO Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Peptide and Oligonucleotide CDMO Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peptide and Oligonucleotide CDMO Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: PolyPeptide Group
  • 7.2: STA Pharmaceutical
  • 7.3: Bachem
  • 7.4: Creative Peptides
  • 7.5: Aurigene Pharmaceutical Services
  • 7.6: Merck
  • 7.7: EUROAPI
  • 7.8: Curia Global
  • 7.9: CordenPharm
  • 7.10: Sylentis